# Klotho

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Mechanism
Updated: 2026-10-14
Canonical: https://heretic.bio/articles/klotho-the-longevity-hormone.html

> Klotho is a protein made mainly in kidney and brain that falls with age; low levels track higher mortality and cognitive decline in large cohorts. In animals the evidence is strong: overexpression extends mouse lifespan about 20-30%, and a single low-dose injection improved memory in aged monkeys. But no human has received klotho in a published trial, and the gene-therapy outfits selling it, including a non-placebo plasmid pilot, are running ahead of the science.

> Klotho is a kidney- and brain-derived protein whose overexpression extends mouse lifespan ~20–30% and whose circulating (soluble) levels decline with age in humans, tracking mortality, kidney decline, and cognitive resilience. A single low-dose injection improved memory in aged monkeys (2023), making klotho one of the most credible "resilience factors" in geroscience — but **zero human interventional data exist as of Aug 2026**. What exists instead is a fast-moving, largely unregulated gene-therapy pipeline (Minicircle plasmid trial [NCT07216781](https://clinicaltrials.gov/study/NCT07216781); Klotho Neurosciences KLTO-202) selling ahead of the science.

## TL;DR Evidence Snapshot

Claim | Evidence | Grade  
---|---|---  
Klotho overexpression extends mouse lifespan ~20–30% | Animal (Kurosu et al., Science 2005) | Strong (preclinical)  
Low serum klotho predicts all-cause mortality in humans | Observational cohorts, incl. NHANES-derived analyses | Moderate (associative)  
Low serum klotho predicts mortality/CKD progression in kidney disease | Systematic reviews/meta-analyses | Moderate-strong (associative)  
Single low-dose klotho injection improves memory in aged primates | Dubal et al., _Nat Aging_ 2023 (n=18 rhesus) | Strong (preclinical, NHP)  
Klotho enhances human cognition / slows human aging | **No human interventional data** | None  
Plasmid klotho gene therapy is safe/beneficial in humans | Phase-1-style industry pilot ([NCT07216781](https://clinicaltrials.gov/study/NCT07216781)), non-placebo, results unpublished | Insufficient  
  
## Discovery and Basic Biology

Klotho was discovered in 1997 when Kuro-o and colleagues serendipitously generated a mouse with a disrupted gene producing a striking **premature-aging phenotype** : growth retardation, arteriosclerosis, osteoporosis, skin atrophy, infertility, and early death (Kuro-o et al., _Nature_ 389:45–50, 1997). The gene was named for Klotho, the Greek Fate who spins the thread of life.

Two functional forms exist:

  1. **Membrane klotho** — a co-receptor for **FGF23** (phosphate/vitamin-D homeostasis), expressed mainly in kidney tubules and choroid plexus. Its loss explains the phosphate-retention phenotype of klotho-deficient mice.
  2. **Soluble klotho (sKlotho)** — the extracellular domain shed by ADAM10/17 proteases, circulating endocrinely. **This is the form measured in serum and the form implicated in cognition and resilience.**



A key mechanistic puzzle: peripherally administered klotho does **not appreciably cross the blood-brain barrier** , yet enhances hippocampal function — implying an indirect peripheral signaling relay (platelet factors and immune modulation are candidate mediators) rather than direct CNS action.

### Mechanisms (segregated by evidence type)

Mechanism | System | Evidence  
---|---|---  
FGF23 co-receptor; phosphate wasting, vitamin-D catabolism | Membrane klotho, kidney | Extensive mouse genetics  
Suppression of insulin/IGF-1 signaling → FOXO activation | Mouse, in vivo | Klotho-deficient and overexpression models  
Wnt/β-catenin suppression (anti-fibrotic, anti-senescent) | Kidney, lung, skin fibrosis models | Mouse + in vitro  
Enhanced NMDAR (GRIN2B-dependent) synaptic plasticity; GluN2B trafficking | Hippocampus | Mouse (Dubal 2014) → confirmed in aged rhesus (2023)  
Reduced neuroinflammation, protectively shifts microglia | CNS | Mouse  
Vascular protection, anti-calcification (phosphate-driven) | Vascular smooth muscle | Mouse + CKD patient associations  
  
## Human Evidence

### Genetics — the heterozygote advantage

The **KL-VS** variant (F352V) of the _KL_ gene: heterozygous carriers (~20–25% of populations) have higher circulating klotho and show better cognition and larger brain volumes in some cohorts; **homozygosity is deleterious** — a classic overexpression toxicity signal. Heterozygote advantage is the field's standing caution against "more klotho is always better" logic.

### Serum levels (observational)

  * Circulating sKlotho declines with age in large cohorts (NHANES).
  * **Mortality:** low serum klotho associated with all-cause mortality in population-based adults (Kresovich et al., 2021; PMCID [PMC9122743](https://pmc.ncbi.nlm.nih.gov/articles/PMC9122743), cited >95×). A 2024 analysis derived operating cutoffs: **klotho <548.8 pg/mL → ~52% higher all-cause mortality risk; <660.9 pg/mL → ~58% higher** (Liu et al., _Sci Rep_ 2024; DOI [10.1038/s41598-024-52701-4](https://doi.org/10.1038/s41598-024-52701-4)).
  * **Kidney disease:** lower serum klotho linked to all-cause mortality, cardiovascular mortality, and adverse renal outcomes in CKD meta-review (Kanbay et al., 2024; PMCID [PMC11398896](https://pmc.ncbi.nlm.nih.gov/articles/PMC11398896)); inverse association with diabetic-kidney-disease prevalence and mortality (Xie et al., _Diabetol Metab Syndr_ 2025; DOI [10.1186/s13098-025-01729-1](https://doi.org/10.1186/s13098-025-01729-1)).
  * **Cognition:** klotho levels associate with executive function/dementia risk cross-sectionally; causality unproven.



⚠️ **Assay caveat:** serum sKlotho ELISAs are not standardized across manufacturers; absolute cutoff values are not portable between labs. sKlotho is a research biomarker, not a clinical-grade diagnostic.

### Animal intervention evidence

  * **Lifespan:** klotho overexpression extends median mouse lifespan ~20–30% (Kurosu et al., _Science_ 309:1829–33, 2005).
  * **Cognition (mice):** klotho elevation (genetic or protein) enhances learning/memory across aging, Alzheimer's, and Parkinson's models via NMDAR/synaptic mechanisms; klotho overexpression rescues cognitive decline in human-amyloid mice (Dubal et al., _Cell Rep_ 2014; DOI [10.1016/j.celrep.2014.03.076](https://doi.org/10.1016/j.celrep.2014.03.076), PMID [24746767](https://pubmed.ncbi.nlm.nih.gov/24746767/)).
  * **Cognition (aged primates):** a **single low-dose (10 µg/kg) systemic klotho injection** improved memory-domain cognition in 18 aged rhesus macaques within ~4 hours, lasting ~2 weeks (Dubal et al., _Nature Aging_ 3, 2023; PMID [37400721](https://pubmed.ncbi.nlm.nih.gov/37400721)). Critically, the **high dose (100 µg/kg) did not work** — the dose-response is non-monotonic. This is the single most important preclinical result driving clinical interest.



## 2025–2026 Evidence Update

The past 18 months materially expanded the klotho literature. Headline additions:

### Uses

The most consequential 2025 publication. Roig-Soriano et al. (_Mol Ther_ 33(4):1449–65, 2025; PMID [39988871](https://pubmed.ncbi.nlm.nih.gov/39988871); PMCID [PMC11997498](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11997498/)) treated **wild-type C57BL/6 mice at 6 or 12 months with a single intravenous AAV9 vector encoding the secreted klotho splice form (s-KL)**. Outcomes at 24 months (~70 human years):

  * **Lifespan:** median increase **15–20%** (Kuro-o's earlier 30–40% result used full-length genetic overexpression; this is the first AAV-based, single-dose, secreted-only replication).
  * **Muscle:** larger fibers, less fibrosis, improved regeneration.
  * **Bone:** preserved trabecular structure (osteoporosis-protective signal), more pronounced in females.
  * **Brain:** increased hippocampal neurogenesis and immune activity.



Independent commentary notes **KL injections at younger age produced lower serum KL** than at 12 months — implying the youthful klotho-axis is already at capacity, and only the aging host benefits from supplementation. This re-frames "klotho as anti-aging drug" as a **deficiency-replacement, not supra-physiological boost, model** — directly undercutting the permanent-overexpression plasmid logic of Minicircle.

### Cardiometabolic comorbidity (NHANES 2025)

Wang et al., _Sci Rep_ 15:16722 (2025; DOI [10.1038/s41598-025-01580-4](https://doi.org/10.1038/s41598-025-01580-4)), n=11,198 NHANES 2007–2016 participants 40–79 yrs:

  * α-Klotho inversely associated with CVD, obesity, CKD, NAFLD.
  * **U-shape** for T2DM, **L-shape** for CKD.
  * OR for cumulative metabolic comorbidity burden in CVD = 0.56 (95% CI 0.35–0.91).
  * CKD mediates ~20% of the klotho → CVD association.
  * Higher klotho → lower all-cause mortality **only among those with CMDs** (interaction), not healthy participants — consistent with klotho as a **stress-response / resilience factor** , not a generalized longevity tonic.



### Cognition / dementia — three converging 2025–2026 papers

  1. **Yang et al. 2026** (_Alzheimers Dement_ 22(4):e71397, PMID [41996134](https://pubmed.ncbi.nlm.nih.gov/41996134), PMCID [PMC13089206](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13089206/)), n=354 older adults with Aβ-PET, tau-PET, plasma p-tau217, GFAP, NfL, cognition: **plasma klotho attenuates AD biomarkers and cognitive decline — but only in APOE ε4 carriers.** Plasma klotho × APOE-ε4 interaction significant for p-tau217, GFAP, NfL, Aβ-PET, cognition. AD biomarkers mediate the cognitive protection. This is the first concrete human evidence of a klotho × APOE-ε4 synergy in AD.
  2. **Katonova et al. 2025** (_Alz Res Ther_ ; DOI [10.1186/s13195-025-01878-5](https://doi.org/10.1186/s13195-025-01878-5)) — KL-VS heterozygosity associated with α-klotho protein levels and **AD risk modification in aMCI/AD dementia**.
  3. **Raber et al. 2025** (_Front Aging Neurosci_ 17:1599402; DOI [10.3389/fnagi.2025.1599402](https://doi.org/10.3389/fnagi.2025.1599402)) — CSF α-klotho **higher in controls than dementia patients** ; correlated with Aβ40/Aβ42 in a species- and cognitive-health-dependent fashion; estrogen HT increased CSF α-klotho in ovariectomized rhesus.
  4. **Systematic review / meta-analysis (2025)** — α-Klotho, serum and plasma levels all associated with cognition / dementia; proposed as a biomarker panel component (Sci Direct [S1876201825000607](https://www.sciencedirect.com/science/article/abs/pii/S1876201825000607)).



### CSF klotho is a research, not clinical, biomarker — same caveat as serum

Assay heterogeneity (ELISA manufacturer differences; pre-analytical CSF handling) and lack of a reference standard mean reported absolute values are **not portable across labs**. Treat klotho as a research-grade aging biomarker for now.

## Pipeline and Competitive Landscape (Aug 2026)

Program | Sponsor | Modality | Status | Honest read  
---|---|---|---|---  
[NCT07216781](https://clinicaltrials.gov/study/NCT07216781) | Minicircle (Belize ops, US-adjacent) | Injectable **non-viral plasmid** klotho, healthy adults, non-placebo pilot | Started Oct 2025; primary completion est. Aug 2026; company claims "proof of concept completed spring 2026" | No peer-reviewed results; non-placebo design limits signal; marketed as platform ("expected to launch 2026") ahead of evidence — classic gray-market pattern (see [Peptide Sciences Shutdown - Gray Market Collapse 2026](peptide-sciences-shutdown-us-gray-market-collapse-fda-enforcement-wave.html))  
KLTO-202 | Klotho Neurosciences (Nasdaq: KLTO) | AAV vector delivering secreted-Klotho (s-KL) splice variant; ALS lead indication, also AD/PD | **FDA Orphan Drug Designation granted Jul 2025** ; manufacturing/process-dev ongoing (est. 8 mo, mid-2026); FDA pre-IND talks; Phase 1 ALS trial targeted late 2026/2027 | First legitimate FDA engagement for klotho gene therapy; ALS is a faster regulatory path than healthy-adult longevity. Still pre-clinical in published peer review.  
Academic klotho-protein trials | Dubal lab / collaborators (UCSF, UPenn) | Recombinant sKlotho dosing studies "being explored" | Pre-registration / exploration | The scientifically credible route; watch for first RCT  
AAV9-sKL translational program | Roig-Soriano / Chillón (UAB) → Klotho Neurosciences license | AAV9-delivered secreted klotho (mouse 20% lifespan result) | Mouse data published 2025; IND-enabling toxicology not yet announced | The strongest scientific foundation; partnership with Klotho Neurosciences suggests IND-enabling work via that channel  
  
**Context:** Minicircle's [NCT07216781](https://clinicaltrials.gov/study/NCT07216781) record cites the Dubal mouse and monkey papers as its scientific basis — but plasmid-mediated **continuous overexpression** is pharmacologically the opposite of the **single low-dose transient pulse** that worked in monkeys. Nothing in the primate data supports the dosing logic of a permanent-expression plasmid; combined with homozygous KL-VS toxicity and high-dose failure in monkeys, the risk ledger is unfavorable until independent data appear.

## Raising Klotho Without Gene Therapy (Evidence-Based)

Lever | Effect on sKlotho | Evidence  
---|---|---  
**Aerobic exercise** | ↑ moderate; ≥12 weeks chronic aerobic training significantly elevates circulating sKlotho | Meta-analyses of RCTs (e.g., de Luca Corrêa et al. 2022, [PMC9585050](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585050/); confirmed in PD cohort 2025, npj Parkinsons Dis); best-supported non-pharmacologic intervention  
**Vitamin D repletion** | ↑ (klotho expression is vitamin-D responsive) | Human observational + trials  
**Estrogen / hormone therapy** | ↑ CSF α-klotho in ovariectomized NHPs (Raber 2025) | NHP — translation to human uncertain  
**Phosphate restriction** | ↑ / protective | Mechanistic + CKD data; avoid excess processed-food phosphate, colas  
**Smoking cessation / glycemic control** | ↑ (smoking and diabetes lower klotho) | Observational  
**Approved drug to raise klotho** | — **none exists** | —  
  
Related: [Exercise Science and Longevity](exercise-science-and-longevity.html), [Vitamin D Optimization](vitamin-d-optimization.html), [Metabolic Health and Insulin](metabolic-health-and-insulin.html).

## Hype Ledger (What Klotho Is NOT)

  * **Not a demonstrated human cognitive enhancer** — no human has received klotho protein under controlled conditions with published results.
  * **Not dose-linearly beneficial** — monkey high-dose failure + homozygous KL-VS harm argue for tight therapeutic windows.
  * **Not validated as a clinical biomarker** — assay non-standardization; association ≠ causation for mortality links.
  * **Not an argument for unregulated plasmid clinics** — permanent overexpression in healthy 23+ adults has no primate safety basis; [Peptide Sources and Quality](peptide-sources-and-quality.html) logic applies with more force to gene therapy.

## Sources

1. ClinicalTrials.gov NCT07216781 — Minicircle klotho plasmid pilot (last update Feb 2026). (NCT07216781)
2. Kresovich JK, et al. Low serum klotho associated with all-cause mortality among population-based adults. PMCID PMC9122743 . (PMC9122743)
3. Liu L, et al. Optimal cut-off values of klotho for predicting all-cause mortality. Sci Rep . 2024. DOI 10.1038/s41598-024-52701-4 . (DOI 10.1038/s41598-024-52701-4)
4. Kanbay M, et al. The association between klotho and kidney and cardiovascular outcomes. 2024. PMCID PMC11398896 . (PMC11398896)
5. Xie P, et al. Associations of serum klotho with diabetic kidney disease. Diabetol Metab Syndr . 2025. DOI 10.1186/s13098-025-01729-1 . (DOI 10.1186/s13098-025-01729-1)
6. Dubal DB, et al. Life extension factor klotho enhances cognition. Cell Rep . 2014;7(4):1065–76. DOI 10.1016/j.celrep.2014.03.076 . PMID 24746767 . (DOI 10.1016/j.celrep.2014.03.076, PubMed 24746767)
7. Dubal DB, et al. Longevity factor klotho enhances cognition in aged nonhuman primates. Nat Aging . 2023;3:943–56. PMID 37400721 . PMC10432271 . (PubMed 37400721, PMC10432271)
8. Roig-Soriano J, et al. Long-term effects of s-KL treatment in wild-type mice: enhancing longevity, physical well-being, and neurological resilience. Mol Ther . 2025;33(4):1449–65. PMID 39988871 . PMCID PMC11997498 . DOI 10.1016/j.ymthe.2025.02.030 . (PubMed 39988871, PMC11997498, DOI 10.1016/j.ymthe.2025.02.030)
9. Wang K, et al. Anti-aging protein α-Klotho is potential for reducing comorbidity risk of cardiometabolic diseases in vulnerable populations and enhancing long-term prognosis. Sci Rep . 2025;15:16722. DOI 10.1038/s41598-025-01580-4 . (DOI 10.1038/s41598-025-01580-4)
10. Yang J, et al. Elevated plasma klotho levels attenuate Alzheimer's disease pathologies and cognitive decline in APOE ε4 carriers. Alzheimers Dement . 2026;22(4):e71397. PMID 41996134 . PMCID PMC13089206 . DOI 10.1002/alz.71397 . (PubMed 41996134, PMC13089206, DOI 10.1002/alz.71397)
11. Katonova A, et al. KLOTHO-VS heterozygosity, α-klotho protein levels, and Alzheimer's disease risk. Alz Res Ther . 2025. DOI 10.1186/s13195-025-01878-5 . (DOI 10.1186/s13195-025-01878-5)
12. Raber J, et al. α-klotho as a biomarker of amyloid β levels in the cerebrospinal fluid. Front Aging Neurosci . 2025;17:1599402. DOI 10.3389/fnagi.2025.1599402 . (DOI 10.3389/fnagi.2025.1599402)
13. de Luca Corrêa H, et al. A systematic review and meta-analysis demonstrating Klotho levels in active adults. 2022. PMCID PMC9585050 . (PMC9585050)
14. Aerobic exercise-induced changes in fluid biomarkers in Parkinson's disease. npj Parkinsons Dis . 2025. DOI 10.1038/s41531-025-01042-8 . (DOI 10.1038/s41531-025-01042-8)